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(S)-N-tert-Butyl-1¶-(4-chlorophenyl)(phenyl)methylsulfamide 
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Source of chirality: Asymmetric catalysis 
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Absolute configuration: 1R 
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1. Introduction 
In the decade or so since Miyaura introduced rhodium-
catalysed addition of arylboron reagents to activated imines 
(2000)[1] a large range of catalytic systems and have been 
developed and the attainment of highly enantioselective 
(>90% ee) versions can be assured in many cases.[2] A 
more pressing problem in this area is to attaining protecting 
groups that simultaneously strongly activate imine 1 to 
addition but also allow mild deprotection of the addition 
products 2 to the commercially interesting 
diarylmethylamines 3 (Scheme 1).[3] NޤTosyl protected 
imines (A) are widely used but the harsh (acidic or highly 
reducing) removal conditions required for 2 cleave many 
other groups.[4] N-Nosylarylimines (B) offer improvements 
but any functionalities in 3 must be tolerant to strong 
nucleophiles (e.g. PhSH).[5] N,N-Dimethylsulfamoyl 
protected imines (C) are robust but can require  
transamination under forcing microwave promotion to 
effect their removal.[6]   Formyl protection (D) does offer 
deprotection under mildly acidic conditions, but in this case 
the imines need to be stored as their sulfinate adducts to 
avoid their decomposition.[7] N-diphenylphosphinoyl 
groups (E) have been popularized by Ellman and others, 
but add significantly to the imine mass.[n8] Finally, Boc 
protection (F) can be used, but this is sometimes too 
labile.[n9] In seeking to balance the requirements of imine 
activation, protecting group stability and ease of removal 
we have suggested that the use of a simple ±SO2- function 
can be effective, as in 4, that can be removed under mildly 
basic conditions (5% water in pyridine) ± conditions 
complementary to groups A-D.[10] However, the presence 
of two stereocentres in 4 complicates their ee assay. To 
avoid such issues we proposed that the use of a  
 
VLPSOH µGXPP\¶ DPLQH LQ the sulfamoyl group ±SO2NHR 
should prove useful. Recently, Lam used the substrates 5 
which are restricted to the use of salicyladehyde derived 
aldimines.[11] This prompts us to disclose our own approach 
here which places no restrictions on Ar1. 
 
Scheme 1. Typical approached to 2-arylethylamines. 
 
 
______________________________________________________________________ 
Sequential reaction of chlorosulfonyl isocyanate with t-BuOH, t-BuNH2 and TFA allows 
formation of  H2NSO2NHBut. Condensation of the latter with Ar1CHO, in the presence of Ti(OEt)4 
provides the activated imines Ar1CH=NSO2NHBut (59-89%). Commercially available boronic 
acids add to these imines with good setereoselectivity (76-98% ee) using readily available diene 
ligands. Simple deprotection with 5% w/w water in pyridine affords free Ar1CHNH2Ar2. 
_______________________________ 
Article history: 
Received 
Accepted 
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2. Results and Discussion 
 
2.1 Synthesis of sulfamyl imine acceptors 9  
An efficient route to the required imines 9 (Scheme 2) uses 
the chemistry of Masui[12] to access the intermediate 
sulfamides 7 directly from N-alkylsulfamoylcarbamates 6. 
The latter are easily prepared by sequential of tert-BuOH 
and aqueous solutions of RNH2 to widely available 
chlorosulfonyl isocyanate; chemistry which presumably 
proceeds via the Burgess-like intermediate 8. No extensive 
purification of intermediates 6 is necessary prior to 
hydrolysis but representative 6b was fully characterised as 
it is a new chemical entity compared to 6a and 6c.[12-14] 
Conversion of 6 to 7 was simply attained by treatment with 
TFA in CH2Cl2 at ambient temperature affording known 7 
in 79-95% yield.[14,15] Preliminary trials using PhCHO 
revealed that the imines 9 were best prepared by Ti(OEt)4 
induced dehydrations, other conditions (cat. H+/Dean-Stark, 
MgSO4, CuSO4) affording low/trace yields.  
 
 
Scheme 2. Preparation of activated imines used in this study. 
 
Investigation of an extensive range of R-substituents in 9[14] 
indicated that the tert-butyl µGXPP\JURXS¶was superior to 
all others for the following reasons - (i) While the 
SO2NHBut group is easily removed under the same 
conditions as 4 deprotection[10] (mild pyridine reflux with 
5% w/w water) the compounds are hydrolytically robust in 
routine usage (much more so than the methyl derivatives 
9a-b). (ii) The released t-BuNH2 is water soluble 
facilitating its simple separation; other substituents (e.g. 
benzyl or aryl derivatives) require chromatographic 
separations. (iii) The tert-butyl derivatives 9c-9i were 
frequently found to be crystalline entities facilitating 
purification. Surprisingly, given these highly attractive 
features, the protecting group in acyclic 9 appears not to 
have been used in additions to imines before as far as we 
can tell ± although it is clearly closely related to 
RCH=NSO2NR2 structures.[6] 
 
2.2. Catalytic 1,2-arylboron additions sulfamyl imines 9 
Our aim was to obtain a system that would enable simple 
access to a wide range of protecting group free diaryl 
amines 3 using simple and widely available (commercial) 
reagents. Among the bewildering array of ligands and 
organoboron sources for catalytic asymmetric additions to 
imines the most readily available are simple boronic acids 
(ArB(OH)2) and the commercialised ligands LA-LB 
(Scheme 3) in the presence of the widely available rhodium 
source [RhCl(CH2=CH2)2]2. 
 
 
Scheme 3. Chiral ligands used in this study. 
Initial optimisation concentrated on imines 9a-d as 
representative examples of electron neutral and moderately 
electron deficient imines in the presence of the  RhI-L 
based catalyst (3 mol% based on 9 using LA or LB). The 
biphasic conditions of Zhou[16] proved most appropriate for 
use of boronic acids (Table 1). 
 
Table 1. Optimisation of catalytic ArB(OH)2 addition to 9.[a] 
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Run Ar1 R Ar2 Solvent 
and base 
Yield 10 
(ee)/% 
Hydrol.
/% 
Using ligand LA 
1 Ph
 
Me 4-ClPh CH2Cl2 
KF 
79 (85) 13 
2 Ph Me 4-ClPh toluene  
KF 
73 (84) 15 
3 4-ClPh Me Ph CH2Cl2 
KF 
42 (n/d) 17 
4 4-ClPh Me Ph toluene  
K2CO3 
87 (71) 7 
5 Ph tBu 4-ClPh toluene  
KF 
83 (86) <2 
6 4-ClPh tBu Ph toluene  
KF 
89 (81) <2 
Using ligand LB 
7 Ph Me 4-ClPh CH2Cl2 
KF 
82 (91) 2 
8 4-ClPh Me Ph CH2Cl2 
KF 
6 (n/d) 92 
9 Ph tBu 4-ClPh toluene  
KF 
84 (94) 0 
10 4-ClPh tBu Ph toluene  
KF 
17 (n/d) 69 
[a]
 Reactions were carried out using 9 (0.5 mmol), Ar2B(OH)2 (1.0 mmol), 
[RhCl(C2H4)2]2 (1.5 mol%), LA (3.3 mol%) and a base (3.8 equiv.) in 
solvent (1 mL) plus water (1 mL) for 16 h at 35 oC. Yields were 
determined by isolation, except runs 3, 8 and 10 which were from 1H 
NMR conversions. Enantioselectivities were determined by HPLC as 
described in Section 4.5. 
 
While interesting levels of enantioselectivity (84-91%) 
were realised in 4-ClPhB(OH)2 additions to N-
methyl/phenyl substituted 9b (Runs 1-2 and 7), additions to 
more electron deficient 9a uniformly resulted in lower ee 
values and appreciable hydrolysis to 4-ClPhCHO together 
with additional byproducts (Runs 3-4 and 8). The presence 
of these species prevented accurate ee assay on the small 
amounts of 10 formed. Despite systematic variation of the 
reaction conditions (solvent, base and catalyst types) no 
overall system could be identified to completely inhibit 
hydrolysis of the N-methyl derivatives 9a-b. Potassium 
carbonate was useful in some cases (Run 4) but 
synthetically useful levels of enantioselectivity could not be 
realised. Attention was switched to the N-tert-butyl 
derivatives 9c-d. While high ee values were realised (81-
94%) unusual system dependent hydrolysis was observed 
(Runs 5-6 and 9-10 highlighted). While that based on 
+D\DVKL¶V (R,R)-bod ligand LB gave an optimal ee for 4-
ClPhB(OH)2 addition to 9d, the same catalyst reproducibly 
only promoted extensive hydrolysis of 9c. Intermediate 
results were attained with LA (Runs 5-6). The yields 
attained of additions products10 are a composite of: (i) 
imine electrophilicity (promoting both addition and 
hydrolysis), (ii) steric/electronic nature of the arylboronic 
acid (controlling the rate of catalyst loading and 
hydrodeboration), (iii) ligand affects controlling the rate of 
catalyst loading and addition.[4] Disentangling these factors 
for a given system is not easy. While the results using N-
tert-butyl derivatives 9c-d were encouraging they raise two 
key questions: (i) given the tendency of these starting 
materials to show catalyst system dependent hydrolysis 
does a wide enough range of synthetic utility exist? and is 
any pattern of reactivity apparent? (ii) Are the final 
products 10 easily deprotected and does this result in any 
stereochemical erosion of the ee realised in the catalytic 
addition? The first of these questions is addressed in Table 
2 and Scheme 4.  
For additions to phenyl-based 9d addition of a significant 
range of Ar2B(OH)2 was tolerated regardless of the ligand 
used. One exception to this was addition of 3-MePhB(OH)2 
where almost complete hydrolysis of the starting imine was 
observed generating 10e in very low yield (7%) when using 
LB. For the substituted imines 9c and 9e-h there were very 
significant issues of hydrolysis in systems using LB. 
Systems that are intolerant of this ligand (<20% yield of 10) 
are summarised in Scheme 4. We could realise no useful 
addition yields to the 4-MePh imine 9g with either LA or 
LB. 
Table 2. Tolerated combinations of ArB(OH)2 and 9.[a] 
 
9 Ar1 Ar2 L 
used 
10 Yield 
(ee)/% 
9c 4-ClPh
 
Ph LA (S)-10a 89 (81) 
9d Ph 4-ClPh LA (R)-10a 83 (86) 
9d Ph 4-ClPh LB (R)-10a 84 (94) 
9d Ph 4-FPh LA (R)-10b 42 (87) 
9d Ph 4-FPh LB (R)-10b 90 (95) 
9d Ph 4-CF3Ph LA (R)-10c 32 (90) 
9d Ph 4-CF3Ph LB (R)-10c 84 (98) 
9d Ph 4-MePh LA (R)-10d 68 (78) 
9d Ph 4-MePh LB (R)-10d 71 (95) 
9d Ph 3-MePh LA (R)-10e 35 (76) 
9d Ph 3-MeOPh LA (R)-10f 37 (84) 
9d Ph 3-MeOPh LB (R)-10f 91 (97) 
9e 4-FPh Ph LA (S)-10b 41 (80) 
9f 4-CF3Ph Ph LA (S)-10c 71 (78) 
9h 3-MePh Ph LA (S)-10e 53 (85) 
9h 3-MeOPh Ph LA (S)-10f 34 (86) 
[a]
 Reactions were carried out using 9 (0.5 mmol), Ar2B(OH)2 (1.0 mmol), 
[RhCl(C2H4)2]2 (1.5 mol%), LA or LB (3.3 mol%) and KF (3.8 equiv.) in 
toluene:water (2 mL, 1:1) for 16 h at 35 oC. Yields were determined by 
isolation. Enantioselectivities were determined by HPLC as described in 
Section 4.5. 
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Scheme 4. Imine/boronic acid combinations leading to extensive imine 
hydrolysis (isolated yields of 10 given). 
2.3. Deprotection of sulfamide addition products 10 
The principal reason for the development of our monoalkyl 
sulfamide addition products 10 was that they would 
undergo facile deprotection to the free diarylmethylamines 
3 under mild basic conditions with good recovery and no 
racemisation. In a trial (R)-10a (86% ee) was subjected to 
aqueous pyridine deprotection protocol (Scheme 5). 
Pleasingly this provided a very high yielding  conversion to 
the free amine (R)-3a with literature properties that could 
be isolated in 79% yield. Such species are not commonly 
isolated due to polarity/basicity issues resulting in material 
loss. More conveniently, direct treatment of the reaction 
mixture containing (R)-3a with excess Ac2O resulted in in 
situ protecting group exchange to (R)-11a (87% ee) 
allowing us to confirm that essentially no racemisation had 
taken place within the error on the HPLC assay (±1%). In 
fact ee measurement on 11 was by far the most convenient 
method in all cases. 
 
Scheme 5. Representative conditions for racemisation-free deprotection of 
10 and protecting group exchange. 
Application of the tested deprotection strategy across the 
range of compounds allowed facile access to the full range 
of deprotected primary amines (Table 3) without 
degradation of enantioselectivity. While conversion of 10 
to 3 was very high yielding isolation of the amines was 
simplified by formation of their acetamides (in an 
analogous way to Scheme 5). All of the compounds had 
properties identical to materials provided by our previous 
deprotections of 4.[10] Summary conditions for the ee 
determinations are given in the Experimental Section 
(Table 4). 
Table 3. Mild base-promoted deprotection of 10.[a] 
 
 
3 Ar1 Ar2 Chirality Yield 
11/% 
Ee 
11/% 
3a Ph
 
4-ClPh R 79 86 
3b Ph 4-FPh R 88 87 
3c Ph 4-CF3Ph R 99 98 
3d Ph 4-MePh R 78 95 
3e 3-MePh Ph S 78 85 
3f Ph 3-MeOPh R 73 97 
 [a]
 Reactions were carried out using isolated samples of 10 prepared from 
9 (0.5 mmol).  
3. Conclusions 
In conclusion the N-tert-butyl-sulfamyl group has been 
developed as a new activating group for imines. The imines 
are simply prepared by condensation of the N-tert-butyl-
sulfamide and an arylaldehyde in the presence of Ti(OEt)4. 
The required N-tert-butyl-sulfamide can be readily 
prepared from tert-BuNH2 and chlorosulfonyl isocyanate in 
two high yielding steps. Rhodium catalysed addition of aryl 
boronic acids proceeds in varying yields; the optimum yield 
being achieved with the LB ligand and the unsubstituted 
benzaldehyde derived imine 9d. These aryl additions give 
enantioenriched sulfamides with excellent enantiomeric 
excess. However, in some cases extensive hydrolysis of the 
precursor imine is observed. This could be moderated by 
use of ligand LA. Deprotection of the resultant addition 
products with 5% w/w water in pyridine is very high 
yielding and proceeds without loss of enantiomeric excess. 
Overall the procedure is complementary to existing routes 
to 3 that normally require rather harsher deprotection 
strategies under either acidic or reductive conditions, or in 
the presence of strong nucleophiles. 
 
4.  Experimental 
4.1 General 
The general instrumentation used has been described 
previously.[10,14] All reactions involving air sensitive 
materials were carried out under argon using standard 
Schlenk techniques. Ligands LA-LB were commercial 
products or prepared by literature procedures.[17] 
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4.2 Representative preparation of N-
alkylsulfamoylcarbamates tert-Butyl N-tert-
butylsulfamoylcarbamate 6b 
Chlorosulfonyl isocyanate (8.7 mL, 0.1 mol, 1 equiv.) in 
toluene (10 mL) was added dropwise to a stirred solution of 
tert-butanol (9.4 mL, 0.1 mol, 1 equiv.) in toluene (100 mL) 
at 3 °C over 30 min. The colourless suspension was stirred 
at 3 °C for 45 min, then pyridine (17.7 mL, 0.22 mol, 2.2 
equiv.) was added dropwise over 15 min and the 
suspension stirred at 7 °C for 60 min. tert-Butylamine (40-
70 wt. % in H2O, 0.6 mol, 6 equiv.) was added dropwise at 
5 °C over 30 min and the biphasic mixture was stirred for 2 
h at 5 °C. The layers were separated, the aqueous was 
washed with toluene (100 mL). The combined organics 
were washed with water (100 mL). The combined aqueous 
were acidified with 2 M HCl to pH 1 and the precipitate 
was collected by filtration to afford the product 6b as a 
colourless crystalline solid (4.51 g, 89%). Rf 0.69 (5% 
MeOH/CH2Cl2); m.p. 151 °C dec.; IR (CHCl3 Ȟmax/cmí1 
3401, 2939, 1737, 1435, 1403, 1143; 1H NMR (400.1 MHz, 
CDCl3 įH 7.11 (s, 1 H, NHBoc), 5.03 (s, 1 H, 
NHC(CH3)3)), 1.50 (s, 9 H, COOC(CH3)3), 1.36 (s, 9 H, 
NHC(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 150.2 (C), 
83.5 (C), 55.0 (C), 29.4 (CH3), 28.1 (CH3); HRMS (ESI 
Positive) calcd. for C9H20N2O4S, [M+Na] 275.1036, found 
275.1042; Anal. Calc. for C9H20N2O4S: C, 42.84; H, 7.99; 
N, 11.10%. Found: C, 42.62; H, 7.97; N, 11.05%. Other 
derivatives of 6 were prepared in analogous manner and 
had literature properties.[13,14] 
 
4.3 General procedure for formation of sulfamides 7 
Trifluoroacetic acid (240 mmol) in CH2Cl2 (20 mL) was 
added dropwise to a stirred suspension of N-
alkylsulfamoylcarbamate 6 (80 mmol) in CH2Cl2 (100 mL) 
at 0 °C. The solution was stirred overnight and allowed to 
warm to ambient temperature. The solution was 
concentrated in vacuo and the residue was taken up in 
EtOAc (75 mL), washed with sat. NaHCO3 solution (2 × 50 
mL), dried (Na2SO4) and concentrated to a colourless oil. 
Compound 7b required no purification. All other species 
were isolated by column chromatography (5% 
MeOH/CH2Cl2) as crystalline solids or pale oils with 
literature properties.[14,15] Rf 7a 0.24 (10:1 CH2Cl2:MeOH), 
1H NMR (400.1 MHz, acetone-d6įH 5.81 (br s, 2 H, NH2), 
5.51 (br s, 1 H, NHCH3), 2.71 (d, J = 5.2 Hz, 3 H, NHCH3); 
7b Rf 0.16 (5% MeOH/CH2Cl2), 1H NMR (400.1 MHz, 
CDCl3 įH 6.40 (br s, 2H, NH2), 6.30 (br s, 1H, 
NHC(CH3)3), 1.24 (s, 9H, C(CH3)3); Rf 7c 0.22 (5% 
MeOH/CH2Cl2), 1H NMR (400.1 MHz, DMSO-d6įH 9.46 
(s, 1 H, NHPh), 7.28-7.23 (m, 2 H, CHaryl), 7.17-7.14 (m, 2 
H, CHaryl), 7.06 (br s, 2 H, NH2) 6.96 (tt, J = 7.2, 1.1 Hz, 1 
H, CHaryl). 
4.4 General Method for synthesis of sulfamyl imines 9 
N-Alkylsulfamide 7 (3.63 mmol, 1 equiv.) was added to a 
stirred solution of arylaldehyde (4.00 mmol, 1.1 equiv.) and 
Ti(OEt)4 (1.95g, 7.26 mmol, 2 equiv.) in THF (10 mL). The 
solution was stirred at reflux for 7 h. Allowed to cool then 
poured into stirred brine (100 mL), EtOAc (50 mL) was 
added and the mixture stirred vigorously. The mixture was 
then filtered through Celite® and flushed with further 
EtOAc. The filtrate was separated and the aqueous was 
back extracted with EtOAc (50 mL). The combined 
organics were washed with brine (50 mL), dried (Na2SO4) 
and concentrated to a cream solid. Purification by column 
chromatography or trituration gave the product as a 
colourless to cream solids (yellow for 9f). 
4.4.1 N-Methyl-N'-[4-
chlorophenylmethylidene]sulfamide 9a 
Prepared from 7a (1.10 g, 10 mmol) and 4-
chlorobenzaldehyde (1.55 g, 11 mmol) and purified by 
column chromatography (2:1 pet. ether:EtOAc) to give a 
colourless solid (1.60 g, 67%). Rf 0.23 (2:1 pet. 
ether:EtOAc); m.p. 135-137 °C; IR (CHCl3Ȟmax/cmí1 3388, 
1611, 1594, 1338, 1162, 842; 1H NMR (400.1 MHz, CDCl3) įH 8.88 (s, 1 H, N=CH), 7.88 (dt, J = 8.4, 2.3 Hz, 2 H, 
CHaryl), 7.50 (dt, J = 8.4, 2.2 Hz, 2 H, CHaryl), 4.44 (br q, J 
= 5.2 Hz, 1 H, NH), 2.84 (q, J = 5.2 Hz, 3 H, CH3); 13C 
NMR (100.6 MHz, CDCl3įC 168.5 (CH), 141.1 (C), 132.0 
(CH), 130.8 (C), 129.6 (CH), 29.9 (CH3); HRMS (ESI 
Positive) calcd. for C8H9N2O2S, [M+Na] 254.9965, found 
254.9974; Anal. Calc. for C8H9N2O2S: C, 41.29; H, 3.90; N, 
12.04%. Found: C, 41.24; H, 3.86; N, 11.82%. 
4.4.2 N-Methyl-N'-[phenylmethylidene]sulfamide 9b 
Prepared from 7a (3.30 g, 30 mmol) and benzaldehyde 
(3.37 mL, 33 mmol), trituration with hexanes gave a cream 
solid (5.09 g, 86%). Rf 0.19 (4:1 pet. ether:EtOAc); m.p. 
127-130 °C; IR (CHCl3Ȟmax/cmí1 3386, 1610, 1578, 1336, 
1161, 842; 1H NMR (400.1 MHz, CDCl3įH 8.93 (s, 1 H, 
N=CH), 7.96-7.93 (m, 2 H, CHaryl), 7.64 (tt, J = 1.6, 7.4 Hz, 
1 H, CHaryl), 7.55-7.51 (m, 2 H, CHaryl), 4.42 (d, J = 5.2 Hz, 
1 H, NHCH3), 2.84 (d, J = 5.2 Hz, 3 H, NHCH3); 13C NMR 
(100.6 MHz, CDCl3įC 170.0 (CH), 134.6 (CH), 132.3 (C), 
130.9 (CH), 129.2 (CH), 29.9 (CH3); HRMS (ESI Positive) 
calcd. for C8H10N2O2S, [M+Na] 221.0355, found 221.0359; 
Anal. Calc. for C8H10N2O2S: C, 48.47; H, 5.08; N, 14.13%. 
Found: C, 48.28; H, 5.14; N, 13.99%. 
4.4.3 N-tert-Butyl-N'-[4-
chlorophenylmethylidene]sulfamide 9c 
Prepared from 7b (1.40 g, 9.2 mmol) and 4-
chlorobenzaldehyde (1.42 g, 10.1 mmol) purified by 
column chromatography (4:1 pet. ether:EtOAc) to give a 
colourless solid (1.21 g, 85%). Rf 0.32 (4:1 pet. 
ether:EtOAc); m.p. 111-114 °C; IR (CHCl3Ȟmax/cmí1 3386, 
2980, 1614, 1595, 1334, 1150, 999, 868; 1H NMR (400.1 
MHz, CDCl3įH 8.87 (s, 1 H, N=CH), 7.85 (dt, J = 8.4, 2.1 
Hz, 2 H, CHaryl), 7.49 (dt, J = 8.4, 2.0 Hz, 2 H, CHaryl), 4.46 
(s, 1 H, NHC(CH3)3)), 1.39 (s, 9 H, C(CH3)3); 13C NMR 
(100.6 MHz, CDCl3įC 166.4 (CH), 140.7 (C), 131.8 (CH), 
131.1 (C), 129.6 (CH), 55.1 (C), 30.2 (CH3); HRMS (ESI 
Positive) calcd. for C11H15ClN2O2S, [M+Na] 297.0435, 
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found 297.0441; Anal. Calc. for C11H15ClN2O2S: C, 48.08; 
H, 5.50; N, 10.20%. Found: C, 48.05; H, 5.48; N, 10.21%. 
4.4.4 N-tert-Butyl-N'-[phenylmethylidene]sulfamide 9d 
Prepared from 7b (1.14 g, 7.50 mmol) and benzaldehyde 
(0.84 mL, 8.25 mmol) purified by column chromatography 
(4:1 pet. ether:EtOAc) to give a colourless solid (1.49 g, 
83%). Rf 0.33 (4:1 pet. ether:EtOAc); m.p. 103-106 °C; IR 
(CHCl3 Ȟmax/cmí1 3386, 2980, 1613, 1576, 1391, 1333, 
1150, 998, 864; 1H NMR (400.1 MHz, CDCl3įH 8.92 (s, 1 
H, N=CH), 7.93-7.91 (m, 2 H, CHaryl), 7.62 (tt, J = 7.4, 1.5 
Hz, 1 H, CHaryl), 7.53-7.49 (m, 2 H, CHaryl), 4.50 (s, 1 H, 
NHC(CH3)3)), 1.39 (s, 9H, C(CH3)3); 13C NMR (100.6 0+]&'&OįC 167.8 (CH), 134.2 (CH), 132.7 (C), 130.7 
(CH), 129.1 (CH), 55.0 (C), 30.2 (CH3); HRMS(ESI 
Positive) calcd. for C11H16N2O2S, [M+Na] 263.0825, found 
263.0815. Anal. Calc. for C11H16N2O2S: C, 54.98; H, 6.71; 
N, 11.66%. Found: C, 54.82; H, 6.68; N, 11.71%. 
4.4.5 N-tert-Butyl-N'-[4-
fluorophenylmethylidene]sulfamide 9e 
Prepared from 7b (1.14 g, 7.50 mmol) and 4-
fluorobenzaldehyde (0.88 ml, 8.25 mmol) purified by 
column chromatography (4:1 pet. ether:EtOAc) to afford a 
cream solid (1.15 g, 59%). Rf 0.31 (4:1 pet. ether:EtOAc); 
M.p. 103-105 °C; IR (CHCl3) Ȟmax/cmí1 3386, 2939, 1601, 
1510, 1333, 1242, 1149, 999; 1H NMR (400.1 MHz, CDCl3) įH 8.88 (s, 1 H, N=CH), 7.96-7.91 (m, 2 H, CHaryl), 7.22-
7.17 (m, 2 H, CHaryl), 4.63 (s, 1 H, NHC(CH3)3)), 1.39 (s, 9 
H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3) įC 166.4 (C, d, 
1JCF = 256 Hz), 166.3 (CH), 133.1 (CH, d, 3JCF = 10.2 Hz), 
129.0 (C), 116.6 (CH, d, 2JCF = 21.8 Hz), 55.0 (C), 30.1 
(CH3); 19F NMR (376.5 MHz, CDCl3) įF í +506
(ESI Positive) calcd. for C11H15FN2O2S, [M+Na] 281.0730, 
found 281.0724. Anal. Calc. for C11H15FN2O2S: C, 51.15; 
H, 5.85; N, 10.84%. Found: C, 51.10; H, 5.85; N, 10.84%. 
4.4.6 N-tert-Butyl-N'-[4-
(trifluoromethyl)phenylmethylidene]sulfamide 9f 
Prepared from 7b (1.14 g, 7.50 mmol) and 4-
(trifluoromethyl)benzaldehyde (1.13 mL, 8.25 
mmol) purified by column chromatography (2:1 pet. 
ether:EtOAc) to give the product as a yellow solid (1.93 g, 
84%). Rf 0.27 (4:1 pet. ether:EtOAc); m.p. 103-106 °C; IR 
(CHCl3 Ȟmax/cmí1 3386, 2980, 1619, 1324, 1175, 1151, 
1000; 1H NMR (400.1 MHz, CDCl3 įH 8.96 (s, 1 H, 
N=CH), 8.04 (d, J = 8.0 Hz, 2 H, CHaryl), 7.77 (d, J = 8.0 
Hz, 2 H, CHaryl), 4.68 (s, 1 H, NHC(CH3)3), 1.40 (s, 9 H, 
C(CH3)3); 13C NMR (100.6 MHz, CDCl3 įC 166.1 (CH), 
135.7 (C), 135.3 (C, q, 2JCF = 32.8 Hz), 130.7 (CH), 126.1 
(CH, q, 3JCF = 3.8 Hz), 123.4 (C, q, 1JCF = 271 Hz), 55.2 (C), 
30.1 (CH3); 19F NMR (376.5 MHz, CDCl3 įF í
HRMS (ESI Positive) calcd. for C12H15F3N2O2S, [M+Na] 
331.0699, found 331.0689. Anal. Calc. for C12H15F3N2O2S: 
C, 46.75; H, 4.90; N, 9.09%. Found: C, 46.70; H, 4.88; N, 
8.97%. 
4.4.7 N-tert-Butyl-N'-[4-
methylphenylmethylidene]sulfamide 9g 
Prepared from 7b (1.14 g, 7.50 mmol) and p-tolualdehyde 
(0.98 ml, 8.25 mmol) purified by column chromatography 
(4:1 pet. ether:EtOAc) to afford a cream solid (1.69 g, 
88%).  Rf 0.39 (4:1 pet. ether:EtOAc); m.p. 131-134 °C; IR 
(CHCl3) Ȟmax/cmí1 3386, 2979, 1603, 1569, 1332, 1148, 
998, 872; 1H NMR (400.1 MHz, CDCl3 įH 8.87 (s, 1 H, 
N=CH), 7.81 (d, J = 8.0 Hz, 2 H, CHaryl), 7.31 (d, J = 8.0 
Hz, 2 H, CHaryl), 4.38 (br s, 1 H, NHC(CH3)3)), 2.45 (s, 3 H, 
ArCH3), 1.38 (s, 9 H, C(CH3)3); 13C NMR (100.6 MHz, 
CDCl3 įC 167.7 (CH), 145.5 (C), 130.8 (CH), 130.1 (C), 
129.9 (CH), 54.9 (C), 30.1 (CH3), 21.9 (CH3); HRMS (ESI 
Positive) calcd. for C12H18N2O2S, [M+Na] 277.0981, found 
277.0982. Anal. Calc. for C12H18N2O2S: C, 56.67; H, 7.13; 
N, 11.01%. Found: C, 56.70; H, 7.13; N, 10.92%. 
4.4.8 N-tert-Butyl-N'-[3-
methylphenylmethylidene]sulfamide 9h 
Prepared from 7b (1.14 g, 7.50 mmol) and m-tolualdehyde 
(0.97 mL, 8.25 mmol) purified by column chromatography 
(4:1 pet. ether:EtOAc) to give a cream solid (1.44 g, 76%). 
Rf 0.26 (4:1 pet. ether:EtOAc); m.p. 85-88 °C; IR (CHCl3) Ȟmax/cmí1 3386, 2937, 1583, 1391, 1333, 1149, 997; 1H 
NMR (400.1 MHz, CDCl3įH 8.88 (s, 1 H, N=CH), 7.73-
7.69 (m, 2 H, CHaryl), 7.44-7.37 (m, 2 H, CHaryl), 4.51 (br s, 
1 H, NH), 2.42 (s, 3 H, ArCH3), 1.39 (s, 9 H, C(CH3)3); 13C 
NMR (100.6 MHz, CDCl3įC 168.1 (CH), 139.0 (C), 135.2 
(CH), 132.6 (C), 130.9 (CH), 129.0 (CH), 128.2 (CH), 55.0 
(C), 30.2 (CH3), 21.2 (CH3); HRMS (ESI Positive) calcd. 
for C12H18N2O2S, [M+H] 277.0981, found 277.0989. Anal. 
Calc. for C12H18N2O2S: C, 56.67; H, 7.13; N, 11.01%. 
Found: C, 56.58; H, 7.13; N, 11.01%. 
4.4.9 N-tert-Butyl-N'-[3-
methoxyphenylmethylidene]sulfamide 9i 
Prepared from 7b (1.14 g, 7.50 mmol) and 3-
methoxybenzaldehyde (1.00 ml, 8.25 mmol) purified by 
column chromatography (4:1 pet. ether:EtOAc) to afford a 
cream solid (1.80 g, 89%). Rf 0.26 (4:1 pet. ether:EtOAc); 
m.p. 90-93 °C; IR (CHCl3 Ȟmax/cmí1 3386, 2941, 1581, 
1333, 1150, 998, 869; 1H NMR (400.1 MHz, CDCl3 įH 
8.87 (s, 1 H, N=CH), 7.48-7.39 (m, 3 H, CHaryl), 7.16 (ddd, 
J = 8.0, 2.8, 1.6 Hz, 1 H, CHaryl), 4.57 (br s, 1 H, 
NHC(CH3)3)), 3.87 (s, 3 H, OCH3), 1.39 (s, 9 H, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3įC 167.8 (CH), 160.1 (C), 
134.0 (C), 130.1 (CH), 124.4 (CH), 121.1 (CH), 113.4 
(CH), 55.5 (CH3), 55.0 (C), 30.1 (CH3); HRMS (ESI 
Positive) calcd. for C12H18N2O3S, [M+Na] 293.0930, found 
293.0927. Anal. Calc. for C12H18N2O3S: C, 53.31; H, 6.71; 
N, 10.36%. Found: C, 53.26; H, 6.67; N, 10.24%. 
4.5 General method for rhodium catalysed boronic acid 
addition to sulfamyl imines 9 
A flame dried Schlenk was charged with [RhCl(C2H4)2]2 PJȝPROPROOLJDQGȝPROPRO%) 
and toluene (0.4 mL), the orange solution was stirred at 
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ambient temperature for 10 min. Toluene (0.6 mL), water 
(1 mL), Ar2B(OH)2 (1 mmol, 2 equiv.), KF (110.4 mg, 1.9 
mmol, 3.8 equiv.) and sulfamyl imine 9 (0.5 mmol, 1 equiv.) 
were added sequentially. The biphasic mixture was gently 
stirred at 35 °C for 16 h. Water (10 mL) added and washed 
with CH2Cl2 (2 × 20 mL). The combined organics were 
washed with brine (10 mL), dried (Na2SO4) and 
concentrated. If necessary, undesired by-products could be 
removed by stirring residue in 1:1 CH2Cl2:2 M HCl (10 
mL). Purification by column chromatography gave the final 
products 10 (see individual conditions). 
Authentic racemic samples of 10 were prepared by PhMgCl 
(4.0 equiv.) addition to 9 (0.50 mmol) in THF (10 mL) at 0 
oC. The reactions were allowed to come to ambient 
temperature while being stirred (18 h) followed by standard 
workup. Alternatively Ar2Li was pre-formed in THF at -78 
oC and treated with 9d (3 h, -78 oC) followed by aqueous 
quench and an identical workup. 
4.5.1 (S)-N-tert-Butyl-1¶-(4-
chlorophenyl)(phenyl)methylsulfamide (S)-10a 
Prepared from 9c (137.4 mg, 0.50 mmol) using LA and 
purified by column chromatography (4:1 pet. ether:EtOAc) 
to give a white solid (156.8 mg, 89%); Rf 0.29 (4:1 pet. 
ether:EtOAc); m.p. 157-159 °C; IR (CHCl3Ȟmax/cmí1 3383, 
2980, 1491, 1324, 1145; 1H NMR (400.1 MHz, CDCl3įH 
7.36-7.26 (m, 9 H, CHaryl), 5.59 (d, J = 6.7 Hz, 1 H, 
NHCH), 4.85 (d, J = 6.7 Hz, 1 H, NHCH), 4.02 (s, 1 H, 
NHC(CH3)3), 1.18 (s, 9 H, C(CH3)3); 13C NMR (100.6 
MHz, CDCl3 įC 140.9 (C), 140.0 (C), 133.2 (C), 128.8 
(CH), 128.7 (CH), 128.6 (CH), 127.8 (CH), 127.4 (CH), 
60.8 (CH), 54.2 (C), 29.5 (CH3); HRMS (ESI Positive) 
calcd. for C17H21ClN2O2S, [M+Na] 375.0904, found 
375.0916. Anal. Calc. for C17H21ClN2O2S: C, 57.86; H, 
6.00; N, 7.94%. Found: C, 57.63; H, 6.02; N, 7.77%. HPLC: 
Daicel Chiralpak OD-H, 95:5 hexanes:iPrOH; 1.0 mL/min; 
200 nm; (S)-enantiomer tS = 22.2 min, (R)-enantiomer tR = 
30.1 min; [Į]D   í1.9 (c = 1.09, CHCl3, for 81% ee 
material). A sample of (R)-10a (83% yield, 94% ee) was 
prepared from 9d and LB which showed equivalent 
properties aside from its optical rotation. 
4.5.2 (R)-N-tert-Butyl-N¶-(4-
fluorophenyl)(phenyl)methylsulfamide (R)-10b 
Prepared from 9d (120 mg, 0.50 mmol) using LB and 
purified by column chromatography (4:1 pet. ether:EtOAc) 
to give a colourless solid (151 mg, 90%). Rf 0.25 (4:1 pet. 
ether:EtOAc); m.p. 133-135 °C; IR (CHCl3Ȟmax/cmí1 3383, 
2980, 1606, 1510, 1322, 1144, 991; 1H NMR (400.1 MHz, 
CDCl3 įH 7.36-7.26 (m, 7 H, CHaryl), 7.04-6.98 (m, 2 H, 
CHaryl), 5.60 (d, J = 6.8 Hz, 1 H, NHCH), 4.89 (d, J = 6.8 
Hz, 1 H, NHCH), 4.05 (s, 1 H, NHC(CH3)3), 1.17 (s, 9 H, 
C(CH3)3); 13C NMR (100.6 MHz, CDCl3 įC 162.1 (C, d, 
1JCF = 246 Hz), 141.1 (C), 137.1 (C, d, 4JCF = 2.9 Hz), 
129.2 (CH, d, 3JCF = 8.8 Hz), 128.8 (CH), 127.9 (CH), 
127.4 (CH), 115.5 (CH, d, 2JCF = 20.3 Hz), 61.0 (CH), 54.4 
(C), 29.5 (CH3); 19F NMR (376.5 MHz, CDCl3įF í
HRMS (ESI Positive) calcd. for C17H21FN2O2S, [M+Na] 
359.1200, found 359.1197; Anal. Calc. for C17H21FN2O2S: 
C, 60.69; H, 6.29; N, 8.33%. Found: C, 60.58; H, 6.26; N, 
8.22%; HPLC: Daicel Chiralpak OD-H, 95:5 
hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer tS = 
20.1 min, (R)-enantiomer tR = 25.2 min; >Į@D = +0.5 (c = 
0.97, CHCl3, for 95% ee material). A sample of (S)-10b 
(41% yield, 80% ee) was prepared from 9e and LA which 
showed equivalent properties aside from its optical rotation. 
4.5.3 (R)-N-tert-Butyl-N¶-(4-
trifluoromethylphenyl)(phenyl)methylsulfamide (R)-10c 
Prepared from 9d (120 g, 0.50 mmol) using LB and purified 
by column chromatography (4:1 pet. ether:EtOAc) to give a 
colourless solid (162 mg, 84%). Rf 0.13 (4:1 pet. 
ether:EtOAc); M.p. 140-143 °C; IR (CHCl3 Ȟmax/cmí1 
3382, 2979, 1421, 1326, 1169, 1144, 991; 1H NMR (400.1 
MHz, CDCl3įH 7.60 (d, J = 8.0 Hz, 2 H, CHaryl), 7.49 (d, J 
= 8.8 Hz, 2 H, CHaryl), 7.40-7.28 (m, 5 H, CHaryl), 5.67 (d, J 
= 6.4 Hz, 1 H, CHNH), 4.83 (d, J = 6.8 Hz, 1 H, CHNH), 
3.98 (s, 1 H. NHC(CH3)3), 1.19 (s, 9 H, C(CH3)3); 13C 
NMR (100.6 MHz, CDCl3įC 145.3 (C), 140.6 (C), 129.8 
(C, q, 2JCF = 32 Hz), 128.9 (CH), 128.2 (CH), 127.8 (CH), 
127.5 (CH), 125.5 (CH, q, 3JCF = 3.6 Hz), 124.0 (C, q, 1JCF 
= 271 Hz), 61.2 (CH), 54.4 (C), 29.5 (CH3); 19F NMR 
(376.5 MHz, CDCl3įF íHRMS (ESI Positive) calcd. 
for C18H21F3N2O2S, [M+Na] 409.1168, found 409.1167. 
Anal. Calc. for C18H21F3N2O2S: C, 55.95; H, 5.48; N, 
7.25%. Found: C, 55.95; H, 5.47; N, 7.12%; HPLC: Daicel 
Chiralpak OD-H, 95:5 hexanes:iPrOH; 1.0 mL/min; 200 
nm; (S)-enantiomer tS = 13.6 min, (R)-enantiomer tR = 22.1 
min; >Į@D  íc = 1.35, CHCl3, for 98% ee material). A 
sample of (S)-10c (71% yield, 78% ee) was prepared from 
9f and LA which showed equivalent properties aside from 
its optical rotation. 
4.5.4 (R)-N-tert-Butyl-N¶-(4-
methylphenyl)(phenyl)methylsulfamide (R)-10d 
Prepared from 9d (127 mg, 0.50 mmol) using LB and  
purified by column chromatography (4:1 pet. ether:EtOAc) 
to give a colourless solid (119 mg, 71%). Rf 0.33 (4:1 pet. 
ether:EtOAc); m.p. 147-149 °C; IR (CHCl3Ȟmax/cmí1 3384, 
3011, 1321, 1144, 990; 1H NMR (400.1 MHz, CDCl3 įH 
7.34-7.32 (m, 4 H, CHaryl), 7.30-7.25 (m, 1 H, CHaryl), 7.22-
7.20 (m, 2 H, CHaryl), 7.15-7.13 (m, 2 H, CHaryl), 5.59 (d, J 
= 6.4 Hz, 1 H, NHCH), 4.74 (d, J = 6.4 Hz, 1 H, NHCH), 
3.84 (br s, 1 H, NHC(CH3)3), 2.33 (s, 3 H, ArCH3), 1.17 (s, 
9 H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 141.4 (C), 
138.3 (C), 137.5 (C), 129.4 (CH), 128.7 (CH), 127.6 (CH), 
127.5 (CH), 127.4 (CH), 61.5 (CH), 54.3 (C), 29.6 (CH3), 
21.0 (CH3); HRMS (ESI Positive) calcd. for C18H24N2O2S, 
[M+Na] 355.1451, found 355.1450. Anal. Calc. for 
C18H24N2O2S: C, 65.05; H, 7.28; N, 8.43%. Found: C, 
64.98; H, 7.30; N, 8.20%; HPLC: Daicel Chiralpak OD-H, 
95:5 hexanes:iPrOH; 1.0 mL/min; 200 nm; (S)-enantiomer 
tS = 21.1 min, (R)-enantiomer tR = 26.1 min. >Į@D = +3.9 (c 
= 0.99, CHCl3, for 95% ee material). 
4.5.5 (S)-N-tert-Butyl-N¶-(3-
methylphenyl)(phenyl)methylsulfamide (S)-10e 
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Prepared from 9h (120 mg, 0.50 mmol) and LA purified by 
column chromatography (4:1 pet. ether:EtOAc) to give a 
colourless solid (89 mg, 54%). Rf 0.30 (4:1 pet. 
ether:EtOAc); m.p. 90-93 °C; IR (CHCl3Ȟmax/cmí1 3384, 
2978, 1391, 1324, 1144, 990; 1H NMR (400.1 MHz, CDCl3) įH 7.34-7.19 (m, 6 H, CHaryl), 7.14-7.06 (m, 3 H, CHaryl), 
5.57 (d, J = 6.8 Hz, 1 H, CHNH), 4.91 (d, J = 6.4 Hz, 1 H, 
CHNH), 4.05 (s, 1 H, NHC(CH3)3), 2.32 (s, 3 H, ArCH3), 
1.15 (s, 9 H, C(CH3)3); 13C NMR (100.6 MHz, CDCl3įC 
141.4 (C), 141.2 (C), 138.3 (C), 128.60 (CH), 128.55 (CH), 
128.4 (CH), 128.2 (CH), 127.6 (CH), 127.5 (CH), 124.5 
(CH), 61.6 (CH), 54.2 (C), 29.5 (CH3), 21.4 (CH3); HRMS 
(ESI Positive) calcd. for C18H24N2O2S, [M+Na] 355.1451, 
found 355.1450. Anal. Calc. for C18H24N2O2S: C, 65.03; H, 
7.28; N, 8.43%. Found: C, 65.03; H, 7.28; N, 8.41%; HPLC: 
Daicel Chiralpak AD, 95:5 hexanes:iPrOH; 1.0 mL/min; 
200 nm; (S)-enantiomer tS = 26.3 min, (R)-enantiomer tR = 
35.6 min. >Į@D   í c = 1.10, CHCl3, for 85% ee 
material). A sample of (R)-10e (35% yield, 76% ee) was 
prepared from 9d and LA which showed equivalent 
properties aside from its optical rotation. 
4.5.6 (R)-N-tert-Butyl-N¶-(3-
methoxyphenyl)(phenyl)methylsulfamide (R)-10f 
Prepared from 9d (120 mg, 0.50 mmol) and LB purified by 
column chromatography (4:1 pet. ether:EtOAc) to give a 
colourless solid (158 mg, 91%). Rf 0.28 (4:1 pet. 
ether:EtOAc); m.p. 100-103 °C; IR (CHCl3Ȟmax/cmí1 3383, 
2969, 1600, 1321, 1240, 1042; 1H NMR (400.1 MHz, 
CDCl3 įH 7.34-7.32 (m, 6 H, CHaryl), 6.92-6.88 (m, 2 H, 
CHaryl), 6.82-6.80 (m, 1 H, CHaryl), 5.59 (d, J = 6.4 Hz, 1 H, 
NHCH), 4.80 (d, J = 6.8 Hz, 1 H, NHCH), 3.91 (br s, 1 H, 
NHC(CH3)3), 3.78 (s, 3 H, OCH3), 1.18 (s, 9 H, C(CH3)3); 
13C NMR (100.6 MHz, CDCl3 įC 159.8 (C), 142.9 (C), 
141.2 (C), 129.7 (CH), 128.6 (CH), 127.6 (CH), 127.5 
(CH), 119.8 (CH), 113.4 (CH), 112.9 (CH), 61.6 (CH), 
55.2 (CH3), 54.2 (C), 29.5 (CH3); HRMS (ESI Positive) 
calcd. for C18H24N2O3S, [M+Na] 371.1400, found 371.1390. 
Anal. Calc. for C18H24N2O3S: C, 62.04; H, 6.94; N, 8.04%. 
Found: C, 61.90; H, 6.91; N, 8.06%; HPLC: Daicel 
Chiralpak AD, 95:5 hexanes:iPrOH; 0.5 mL/min; 200 nm; 
(S)-enantiomer tS = 95.6 min, (R)-enantiomer tR = 104.0 
min. >Į@D  íc = 1.26, CHCl3, for 97% ee material). A 
sample of (S)-10f (34% yield, 86% ee) was prepared from 
9h and LA which showed equivalent properties aside from 
its optical rotation. 
4.6 Deprotection and acetylation of sulfamides 10, 
formation of 3 and 11 
A solution of the sulfamide 10 (typically ca. 0.4 mmol) in 
5% water-pyridine (10 mL) was stirred at reflux overnight. 
Removal of the solvents afforded the amines 3 directly. 
Alternatively, the solution was allowed to cool and acetic 
anhydride (10 eq) was added, stirred at ambient 
temperature for 7 h. Subsequently 1 M HCl (20 mL) was 
added and the mixture extracted with Et2O (2 × 15 mL). 
The combined organic extracts were washed with 2 M HCl 
(2 × 20 mL), water (20 mL) and brine (20 mL), dried 
(Na2SO4) and concentrated to give the product with no 
further purification necessary. Full data for both the 
amines[7,14] and their acyl derivatives[14,18] are available. 
Summary data for the ee assays on the acetamides 11 are 
given in Table 4. 
Table 4. Enantiopurity determination using 11.[a] 
3 Ar1 Ar2 HPLC conditions[b] [D]D 
11/%[c] 
11a Ph
 
4-ClPh OD, 95:5, 1 mL min-1 
tS = 22.2, tR = 33.6 min 
-1.1 (R, c 
= 1.3, 
87% ee)[d] 
11b Ph 4-FPh OD, 95:5, 1 mL min-1 
tS = 8.8, tR = 13.6 min 
-1.2 (R, c 
= 1.1, 
95% ee) 
11c Ph 4-CF3Ph OD-H, 90:10, 1 mL 
min-1 tS = 6.6, tR = 11.0 
min 
+33.6 (S, 
c = 0.62, 
89% ee)[e] 
11d Ph 4-MePh OD-H, 90:10, 1 mL 
min-1 tS = 8,0, tR = 10.1 
min 
-1.7 (R, c 
= 1.0, 
97% ee) 
11e 3-
MePh 
Ph AH-H+AD in series, 
95:5, 1 mL min-1 tS = 
27.6, tR = 32.0 min 
+1.3 (S, c 
= 1.1, 
85% ee) 
11f Ph 3-
MeOPh 
OD, 95:5, 1 mL min-1 
tS = 13.7, tR = 27.9 min 
n/d 
[a]
 Carried out on acetamides prepared directly from in situ 3 (0.3-0.5 
mmol) by the chemistry of Table 4. 
[b]
 Data in the form: column type, ratio of hexanes:iso-PrOH, flow rate, 
enantiomer elution order. A detector wavelength of 200 nm was used in 
all cases. 
[c]
 At ambient temperature in CHCl3 unless otherwise stated. 
[d]
 In EtOH. 
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